Gerresheimer decisively continues on profitable growth course in financial year 2023
Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts p…
Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts p…
Broad portfolio for biologics, including cell and gene therapy products Digitally connected Drug Delivery Devices for s…
Subcutaneous administration of oncology drugs with digital therapy support Integrating Gx SensAir drug delivery device w…
Significant expansion of production capacities for RTF syringes for the North American market Investment volume of aroun…
. - Suitable for cryogenic storage - High break resistance - Prevention of delamination Gerresheimer, innovative syste…
. - Shatter-resistant injection vials maximize patient and production safety - Optional Velocity coating for outstanding…
Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy suppor…
. − The partnership will combine Gerresheimer’s extensive glass converting expertise with Corning’s Velocity® Vial techn…
Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris. This kit consists of sterile Gx RTF vials in ne…
With innovative, solution-oriented, and sustainable developments, the Gerresheimer team presents itself at Pharmapack an…